Member Info for researcher1

3m if lucky - half the expected - oh dear Emerald, we did warn you.....

Quite - the sooner SCLP partner with someone who demands a US listing the better....

Emerald has filtered me, boo hoo, I'm weepingly upset. I'd return the favour except then there'd be no AN supporter left on this board (wearing a dunce's cap....)

And I seem to have driven the price up! my IG platform is showing today's buys are worth £2800 more already...

It's all so predictable (yet shocking still) that the SP should slump after such news. In the US it probably would have increased by 10% or so - such powerful positive signs all round. Oh well, I'll have to fill my boots all over again....

Same old same old from AN - over-hype a potentially useful agreement prior to paltry results. I can see that in around 5 or 6 years Angle may be on a sound financial footing, but that's if it survives. He really has to go.

Less of the squabbling please children, it doesn't help. I can't pretend I'm not expecting a huge miss on revenue, which will send the SP to new lows. Then, and only then, and depending on fundraising plans, there may just be a long term Buy argument, but I don't think I will until Newland accepts he's a serial liar (he would say 'misjudger') and hands over the tiller.

It is incredible, inexplicable even - until you look at Newland's record.....

Odd isn't it that all Sclp's groundbreaking research relates to a watermelon?

Ah, ok, so you are blaming the pharma companies for not seeing the potential, rather than Newland for garbling it and holding it back because he wants to hold the reins himself? Bless.

Proline, please then speak your golden truths.....?

I agree with much that you say Emerald - I'm just not going to touch a Newland company with a bargepole. I especially agree that he is responsible for holding up cancer research. He's a total disgrace.

Emerald, it's clear you are a Parsortix fan, to the point of boredom. All investors, previous (me) or current, recognise the groundbreaking nature of the technology. But it is being handled by Andrew Newland, the most disdained CEO on the whole of AIM. He has turned the future into a lame dog, licking its own wounds. Parsortix may eventually become state of the art, but not under his management. The best that can be hoped for is that a large pharma recognise the potential, and even then they are not going to pay much for it. Oh, and by the way, watch out for another miss of forecast coming to you soon. AN has not hit one single target, ever.

Decided to wait until tomorrow and try to buy under 17p (only sold 50K)

All seems pretty standard to me - sold some early @ 17.49p and will likely buy back in. few minutes...

Quite right chester

Not worth 7p with AN at the helm...

Lindy speaking of Snapvax: "Combining this technology with our expertise will allow us to develop a rapid manufacturing process for Modi-2, with the hope that we can bring it into a Phase 1 clinical study during 2024." On target then....

Agreed ee - data is king, charts rhubarb.

Yes Ray, Moderna might have to consider investing in better technologies elsewhere.......